Practo, ZocDoc, Doctolib: Are a Wave of Healthcare Appointment Booking IPOs on the Horizon?

Why It Matters

The IPO surge signals that health‑tech platforms have achieved the scale, AI‑driven efficiency and financial discipline required for public‑market credibility, reshaping digital‑health investment dynamics.

Key Takeaways

• ZocDoc trades 67% below 2021 valuation, yet shows 6.9% 90‑day ROI.
• Doctolib targets $6‑8 B IPO valuation after $376 M ARR run‑rate.
• Practo aims $700 M pre‑IPO valuation, achieving first positive EBITDA.
• Generative AI now core to health‑tech platforms, driving higher margins.
• 2026 health‑tech IPOs expected at 10‑20% discount vs SaaS peers.

Pulse Analysis

The 2026 health‑tech IPO window reflects a broader macro‑economic reset. After years of pandemic‑driven capital inflows, interest rates have steadied and global GDP growth has rebounded, allowing investors to re‑evaluate valuations with a focus on profitability. This environment favours companies that have moved beyond speculative growth to demonstrable unit economics, creating a fertile ground for large‑scale exits that can inject liquidity back into the venture ecosystem.

At the centre of this wave are ZocDoc, Doctolib and Practo, each leveraging generative AI to transform both patient‑facing and back‑office functions. ZocDoc’s transaction‑fee model has delivered EBITDA profitability since 2019, and despite a 67% discount to its 2021 $1.8 billion round, the platform posted a 6.9% three‑month return in early 2026. Doctolib, Europe’s e‑health leader, reported €348 million (≈$376 million) ARR in 2024 and is targeting a $6‑8 billion IPO valuation as it nears breakeven. Practo, after turning a modest profit in FY 2025, is courting a $125 million pre‑IPO round at a $700 million valuation to fund its US expansion and AI‑enhanced care‑navigation services.

For investors, the convergence of AI‑driven efficiency, solid cash flows and a calibrated valuation landscape makes health‑tech a compelling asset class. The sector’s shift toward unified platforms—integrating EHRs, scheduling and revenue‑cycle management—addresses longstanding fragmentation, promising higher margins and recurring revenue streams. As European firms eye U.S. listings for premium multiples and Asian players ramp up digital‑health infrastructure, the 2026 IPO cohort could set a new benchmark for what public markets expect from health‑technology innovators. This momentum is likely to accelerate capital allocation toward AI‑centric health solutions, reinforcing the transition to a "Health Tech 2.0" era.